Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

NCT03360929 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: AZD3759

Sponsor

LYZZ Alpha Holding Ltd

Collaborators

[object Object]